FSD Pharma Added to Leading Cannabis ETF With Significant 1.9% Weighting

CSE: HUGE
OTCQB: FSDDF
FRA: 0K9

TORONTO, Sept. 27, 2018 /CNW/ - FSD Pharma Inc. ("FSD Pharma" or the "Company") (CSE: HUGE) (OTCQB: FSDDF) (FRA: 0K9) is pleased to announce that Horizons ETFs Management (Canada) Inc. ("Horizons ETFs") has added the Company to the Horizons Marijuana Life Sciences Index ETF ("HMMJ:TSX") as part of the quarterly rebalance of the constituent holdings of HMMJ. The Company stock has a 1.9% weighting in HMMJ. According to Horizons ETFs, "As at September 5, 2018, HMMJ had reached over CAD $1 billion in assets under management – a rare achievement for the Canadian ETF marketplace".¹

"We are thrilled to be included in HMMJ, which is the largest ETF offering direct exposure for investors to North American life sciences companies that have significant business activities in the marijuana industry. FSD Pharma expects to continue to deliver on its current business strategy and expansion plan in preparation for adult-use legalization on October 17, 2018," said Anthony Durkacz, Director of FSD Pharma.

[1] http://www.newswire.ca/en/releases/archive/September2018/26/c3045.html

About FSD Pharma (CSE: HUGE) (OTCQB: FSDDF) (FRA: 0K9)

FSD Pharma through its wholly-owned subsidiary FV Pharma, is a licensed producer of marijuana under the Access to Cannabis for Medical Purposes Regulations (ACMPR) having received its cultivation license on October 13, 2017. Headquartered at the former Kraft plant in Cobourg, Ontario, approximately an hour's drive from Toronto, FV Pharma management's mission is to transform the facility into the largest hydroponic indoor cannabis facility in the world. FV Pharma intends to target all legal aspects of the cannabis industry, including cultivation, processing, manufacturing, extracts and research and development.

Forward-Looking Information
Certain statements contained in this press release constitute forward-looking information. These statements relate to future events or future performance. The use of any of the words "could", "intend", "expect", "believe", "will", "projected", "estimated" and similar expressions and statements relating to matters that are not historical facts are intended to identify forward-looking information and are based on the Corporation's current belief or assumptions as to the outcome and timing of such future events. Actual future results may differ materially. In particular, this release contains forward-looking information relating to the development of the Corporation's indoor cannabis facility and its business goals and objectives. The forward-looking information contained in this press release is made as of the date hereof, and the Corporation is not obligated to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by applicable securities laws. Because of the risks, uncertainties and assumptions contained herein, investors should not place undue reliance on forward looking-information. The foregoing statements expressly qualify any forward-looking information contained herein.

Neither the Canadian Securities Exchange nor its regulation services provider accept responsibility for the adequacy or accuracy of this release.

SOURCE FSD Pharma Inc.

Additional Information: Anthony Durkacz, Director, FSD Pharma Inc., [email protected], 416-720-4360; Contact Information: Investor Relations, Email: [email protected], Website: www.fsdpharma.com